Erratum

Expression and role of PAICS, a *de novo* purine biosynthetic gene in prostate cancer¹

Balabhadrapatruni V. S. K. Chakravarthi^{1,2,3,4,†}, Moloy T. Goswami^{1,2,†}, Satya S. Pathi^{1,2,8}, Matthew Dodson¹, Darshan S. Chandrashekar³, Sumit Agarwal³, Saroj Nepal³, Sai Akshaya Hodigere Balasubramanya³, Javed Siddiqui¹, Robert J Lonigro^{1,5}, Arul M. Chinnaiyan^{1,2,5,6,7}, Lakshmi P. Kunju^{1,2}, Nallasivam Palanisamy^{1,9}, Sooryanarayana Varambally 0000-0002-2277-1127 0000-0002-2277-1127^{1,3,4,*}

¹Michigan Center for Translational Pathology

²Department of Pathology, University of Michigan

³Department of Pathology, University of Alabama at Birmingham

⁴Comprehensive Cancer Center, University of Alabama at Birmingham, AL 35233, USA

⁵Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA

⁶Department of Urology, University of Michigan

⁷Howard Hughes Medical Institute, University of Michigan Medical School

⁸Present Address: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

⁹Present Address: Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI 48202, USA.

[†] Equal first author

*Correspondence to: Sooryanarayana Varambally, Ph.D., Molecular and Cellular Pathology, Department of Pathology, Wallace Tumor Institute, Room # 430, University of Alabama at Birmingham, AL 35233, USA

Phone: (205) 996-1654

Email: soorya@uab.edu

¹ This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:<u>10.1002/pros.23533</u>

This article is protected by copyright. All rights reserved.

The authors regret that the printed version of the above article contained an inadvertent error where a wrong tumor xenograft study was represented due to a mistaken labeling of PC3 prostate lines in another file. We have now repeated the *in vivo* experiments with PAICS knockdown cells and with a non-targeting shRNA as a control, and added the correct **Fig. 3 E.** and **F.**

Figure legend:

Figure 3. (E) PAICS knockdown in PC3 cells inhibits tumor growth in a mouse xenograft model. Athymic nude mice were injected with PC3 cells that had either stable PAICS knockdown or non-targeting shRNA and tumors were monitored at indicated time points and plotted. The solid black line is for Non-T shRNA, the dashed line is for shRNA1 and dotted line is for shRNA2. N = 8 mice per group; *P < 0.009, compared with non-targeting shRNA xenografts. Inset: Immunoblot analysis of PAICS using these stable knockdown lysates. (F) Tumor weights of corresponding mouse xenograft models. Non-targeting shRNA was used as a control. N = 8 mice per group; *P < 0.002, compared with non-targeting shRNA xenografts. The statement with reference 19 " The tumor data obtained using scramble cells is same as used in an earlier study since PAICS tumor xenograft study was conducted simultaneously using common control animals [19]" is no longer relevant since we performed an independent experiment to verify the outcome. Overall conclusions of the article are not affected by this correction. The authors apologize for any inconvenience that these errors may have caused. We are grateful for expert help from Selvarangan Ponnazhagan, Reading Ashton and Jonathan Hensel to complete the additional experiments.




Figure 1